Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokic, Goran, Hillen, Hauke S., Tegunov, Dimitry, Dienemann, Christian, Seitz, Florian, Schmitzova, Jana, Farnung, Lucas, Siewert, Aaron, Höbartner, Claudia, Cramer, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804290/
https://www.ncbi.nlm.nih.gov/pubmed/33436624
http://dx.doi.org/10.1038/s41467-020-20542-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804290/
https://www.ncbi.nlm.nih.gov/pubmed/33436624
http://dx.doi.org/10.1038/s41467-020-20542-0

Ejemplares similares